Cecelia Calhoun

Cecelia Calhoun is an Assistant Professor of Medicine (Hematology) at Yale School of Medicine and Medical Director of the Adult Sickle Cell Program at Smilow Cancer Hospital. Her work integrates clinical care, implementation science, and health equity to improve outcomes for individuals with sickle cell disease (SCD) across their lifespan. She is an NIH-funded investigator collaborating nationally on SCD research and leads initiatives to enhance transition readiness from pediatric to adult care.

• Specialization: Sickle Cell Disease (Hematology/Oncology)
• Research Focus: Implementation Science, Health Equity, Transition to Adult Care, Patient Education
• Education: MBA (Yale, 2021), MPHS (Washington University, 2017), MD (Wayne State, 2011)

Dr. Calhoun’s research spans mixed-methods studies to address educational and healthcare barriers, including video game interventions for transition readiness and cost-effectiveness analyses of curative therapies. She actively participates in peer review groups (e.g., Neuro-Heme Consortium) and serves on journal editorial boards.

Recent publications highlight her work on buprenorphine prescribing disparities, cognitive screening practices, and ASH guideline implementation. Her clinical trials include evaluating novel therapies like BMS-986470 and advancing patient-centered care models.

• Honors: Top Health Professionals Under Forty (2022), Guardian of Childhood (2021), Dean’s Mission & Impact Award (2021)